1000787-75-6

Basic information

• Product Name: 5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine
• Synonyms: 5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine;5-[[6-[2,4-Bis(trifluoromethyl)phenyl]-3-pyridazinyl]methyl]-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine;GS 333126;GS 9190;Tegobuvir;9190/tegobuvir;Tegobuvir (GS-9190)
• CAS NO: 1000787-75-6
• Molecular Formula: C₂₅H₁₄F₇N₅
• Molecular Weight: 517.4009824
• Mol File: 1000787-75-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 558.0±60.0 °C(Predicted)
• Appearance: /
• Density: 1.46
• Solubility: ≥24.95 mg/mL in DMSO; insoluble in H2O; ≥100 mg/mL in EtOH
• PKA: 8.28±0.20(Predicted)
• CAS DataBase Reference: 5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine(1000787-75-6)
• EPA Substance Registry System: 5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine(1000787-75-6)

Safety Data

• Hazardous Substances Data: 1000787-75-6(Hazardous Substances Data)

Usage

references

[1]. zeuzem s, andreone p, pol s, lawitz e, diago m, roberts s, focaccia r, younossi z, foster gr, horban a et al: telaprevir for retreatment of hcv infection. n engl j med 2011, 364(25):2417-2428.[2]. wong ka, xu s, martin r, miller md, mo h: tegobuvir (gs-9190) potency against hcv chimeric replicons derived from consensus ns5b sequences from genotypes 2b, 3a, 4a, 5a, and 6a. virology 2012, 429(1):57-62.[3]. shih ih, vliegen i, peng b, yang h, hebner c, paeshuyse j, purstinger g, fenaux m, tian y, mabery e et al: mechanistic characterization of gs-9190 (tegobuvir), a novel nonnucleoside inhibitor of hepatitis c virus ns5b polymerase. antimicrob agents chemother 2011, 55(9):4196-4203.[4]. behrens se, tomei l, de francesco r: identification and properties of the rna-dependent rna polymerase of hepatitis c virus. embo j 1996, 15(1):12-22.[5]. hebner cm, han b, brendza km, nash m, sulfab m, tian y, hung m, fung w, vivian rw, trenkle j et al: the hcv non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit ns5b polymerase function. plos one 2012, 7(6):e39163.

Upstream product

• 120276-59-7 3-chloro-6-pyridazinyl methyl chloride 
• 1121-79-5 3-chloro-6-methylpyridazine 
• 153254-09-2 2,4-bis(trifluoromethyl)phenylboronic acid 
• 1000787-76-7 5-[6-chloro-pyridazin-3-ylmethyl]-2-(2-fluoro-phenyl)-5H-imidazo[4,5-c]pyridine 
• 1099778-81-0 3-(2,4-bis-trifluoromethyl-phenyl)-6-chloromethyl-pyridazine 
• 89075-43-4 2-(2-fluorophenyl)-3H-imidazo[4,5-c]pyridine 

Relevant articles and documents

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HCV

This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection.